OncLive® Takes a Look Back at Most Listened Podcasts of 2020

OncLive On Air^™

Digital media, now more than ever, has become a primary platform for communication, and in 2020, the production of the OncLive^® podcast, OncLive On Air^™, was put into overdrive to bring practicing oncologists exclusive biweekly interviews, discussions, and insights from leading experts in cancer care.

The top 10 episodes of the year featured an array of key oncologic topics, including the controversy surround the phase 3 ADAURA trial in non–small cell lung cancer (NSCLC), the diagnosis and treatment of patients with essential thrombocythemia (ET), and the role of PARP inhibition in ovarian cancer.

Top 10 Most Listened to OncLive On Air^™ Podcasts in 2020:

• Talking KRAS-Targeted Therapy in NSCLC With Dr. Levy
• Examining ADAURA and the Advantages of Adjuvant Osimertinib in EGFR+ NSCLC
• Mesa and Ulmer Measure Methods for JAK Inhibitor Optimization in Myelofibrosis
• Raez on the Rise of Liquid Biopsy in Lung Cancer
• Physician and Patient Perspectives on Diagnosis and Treatment in Essential Thrombocythemia
• FDA Approval Insights: Olaparib in HRR-Mutant mCRPC
• Talking KRAS-Targeted Therapy in NSCLC With Dr. Drilon
• FDA Approval Insights: Lurbinectedin in Metastatic SCLC
• Herzog and Moore Mull Over the Role of Maintenance PARP Inhibition in Ovarian Cancer
• FDA Approval Insights: Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Since its inception in July 2018, OncLive On Air^™ has grown significantly, moving from once-weekly releases to biweekly releases on Mondays and Thursdays. The podcast, which is geared toward and features practicing oncologists, provides easily digestible and accessible information on drug development, regulatory decisions, clinical applications, and career pathways across oncology.

In partnership with key opinion leaders, OncLive On Air^™ provides perspectives on the topics oncologists want to hear about in episodes ranging from 10 to 45 minutes long.

“Podcasts in cancer allow us to take a deeper dive into a topic, frequently with multiple perspectives, in a way that helps frame the issues for those listening in a way that is easy to access and useful to apply,” said Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center. Mesa was featured in 2 of the top 10 OncLive On Air^™ episodes of 2020, in which he discerned the optimization of JAK inhibitors in myelofibrosis and spoke candidly about the challenges of diagnosing and treating ET with one of his own patients.

Two episodes from the OncLive On Air^™ KRAS-Targeted Therapy in NSCLC series, sponsored by Amgen, were included in the top 10 list featuring Benjamin P. Levy, MD, associate professor of oncology and clinical director of Medical Oncology at Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, and Alexander Drilon, MD, research director of Early Drug Development at Memorial Sloan Kettering Cancer Center.

“Given the rapid emergence of multiple targeted therapies and the quickly shifting therapeutic landscape in NSCLC, podcasts are a quick easy way to stay current and knowledgeable in lung cancer,” Levy said.

Also included in the top 10 list were 3 FDA Approval Insights episodes, which comprise quick recaps of recent FDA approvals that feature a discussion of data that led to the approval, the clinical significance of the regulatory decision, and the next steps for research with the agent.

The top episodes featured:

1. Aditya Bardia, MD, MPH, director of Precision Medicine at the Center for Breast Cancer, founding director of the Molecular and Precision Medicine Metastatic Breast Cancer Clinic at Massachusetts General Hospital Cancer Center, and an assistant professor of medicine at Harvard Medical School, on the FDA approval of sacituzumab govitecan-hziy (Trodelvy) in metastatic triple-negative breast cancer
2. Neeraj Agarwal, MD, professor of medicine, and director of the Genitourinary Oncology Program at Huntsman Cancer Institute at the University of Utah, on the FDA approval of olaparib (Lynparza) in metastatic castration-resistant prostate cancer
3. Jacob Sands, MD, a physician at Dana-Farber Cancer Institute, and an instructor in medicine at Harvard Medical School, on the FDA approval of lurbinectedin (Zepzelca) in recurrent, metastatic small cell lung cancer (SCLC).

In 2021, OncLive On Air^™ is looking to continue the FDA Approval Insights episodes, featuring spotlights on trilaciclib (Cosela), which was approved to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage SCLC, lisocabtagene maraleucel (Breyanzi) in large B-cell lymphoma, and cemiplimab-rwlc (Libtayo) in NSCLC and basal cell carcinoma, among others.

Other topics coming in 2021 include perspectives on COVID-19 and surgery, the multidisciplinary management of high-risk non-melanoma skin cancer, and many others.

“OncLive On Air^™ podcasts are very needed and important,” said Luis E. Raez, MD, medical director of Memorial Cancer Institute, and chief of Hematology/Oncology at Memorial Healthcare System, whose interview was featured in a top 10 episode on the growing role of liquid biopsy in lung cancer. “[These podcasts] address essential and contemporary topics relevant to state-of-the-art cancer care. For this and other reasons, they are well received and used by everybody.”

“[OncLive On Air^™ podcasts] are short, interesting and relevant. Thanks to OncLive^® for inviting me to participate [in] this community contributing to our own education and the education of our advocates and peers,” Raez added.

OncLive On Air™ is available on OncLive.com, Apple Podcasts, and Spotify.

Are you interested in joining us on an episode? Please contact Caroline Seymour at cseymour@onclive.com or Jessica Hergert jhergert@onclive.com for more information.